Pharmaceutical company Actavis PLC is expected to sell more than $20 billion in bonds as early as this week, a deal that would rank as the second-largest corporate bond ever and further propel bond sales this year into record territory. Traders expect the bonds to fly off the shelves, with investors globally searching for income-generating investments at a time of low rates on safe government debt.